UBS Initiates Coverage On CG Oncology with Buy Rating, Announces Price Target of $60
Portfolio Pulse from Benzinga Newsdesk
UBS analyst David Dai has initiated coverage on CG Oncology (NASDAQ:CGON) with a Buy rating and set a price target of $60.
October 24, 2024 | 11:26 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
UBS has initiated coverage on CG Oncology with a Buy rating and a price target of $60, indicating a positive outlook for the stock.
The initiation of coverage by UBS with a Buy rating and a $60 price target suggests a positive sentiment from a reputable financial institution. This is likely to boost investor confidence and could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100